Radioactive beads plus immunotherapy: a new hope for liver cancer?

NCT ID NCT07334483

Recruiting now Disease control Sponsor: GrandPharma (China) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests a treatment for liver cancer that cannot be removed by surgery. It uses tiny radioactive beads (yttrium-90) alone or combined with immunotherapy (camrelizumab) and/or a targeted drug (apatinib). The goal is to see if these combinations work better than the standard chemoembolization (cTACE) at shrinking tumors and delaying cancer growth. About 120 adults with non-metastatic liver cancer will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITING

Nanjin, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HCC